文献速递浆细胞疾病

浆细胞疾病患者循环多发性骨髓瘤细胞的计数与特征分析

Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
PubMed 文献 · Br J Haematol · 2017-11-05

研究开发自动化检测方法计数并表征外周血循环多发性骨髓瘤细胞(CMMC),检测超1000例患者样本。新诊断骨髓瘤中CMMC计数与骨髓浆细胞比例、血清M蛋白及ISS分期相关,缓解后显著下降(P<0.001)。缓解时CMMC≥100者生存较<100者差,SMM中高危进展者CMMC显著高于未进展者(P=0.031)。

要点

  • 新诊断骨髓瘤患者CMMC计数与骨髓浆细胞比例、血清M蛋白及ISS分期相关。
  • 治疗达缓解后CMMC计数较基线显著下降(P<0.001)。
  • 缓解时CMMC≥100者生存较<100者差,检测不到CMMC者总生存进一步获益。

核心结论

  • CMMC可无创监测肿瘤生物学,可能作为浆细胞疾病患者的预后检测工具。

研究设计与样本

  • 开发自动化检测方法,从浆细胞疾病患者外周血中计数并表征循环多发性骨髓瘤细胞(CMMC)。
  • 检测超过1000例患者样本,包括新诊断多发性骨髓瘤及高危/中危冒烟型多发性骨髓瘤(SMM)的独立队列,并有临床随访数据。

主要发现

  • CMMC表达骨髓瘤特征性基因,其荧光原位杂交结果与骨髓结果相关性良好。
  • 新诊断骨髓瘤患者中,CMMC计数与骨髓浆细胞百分比、血清M蛋白及国际分期系统(ISS)分期相关。
  • 治疗达缓解后CMMC计数较基线显著下降(P<0.001)。
  • 缓解时CMMC计数≥100的患者较<100的患者生存缩短,检测不到CMMC者总生存进一步获益。
  • SMM队列中,更高危骨髓瘤前驱状态患者CMMC呈升高趋势;中危/高危SMM进展者CMMC计数显著高于未进展者(P=0.031)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We have developed an automated assay to enumerate and characterize circulating multiple myeloma cells (CMMC) from peripheral blood of patients with plasma cell disorders. CMMC show expression of genes characteristic of myeloma and fluorescence in situ hybridisation results on CMMC correlated well with bone marrow results. We enumerated CMMC from over 1000 patient samples including separate cohorts of newly diagnosed multiple myeloma and high/intermediate risk smouldering multiple myeloma (SMM) with clinical follow-up data. In newly diagnosed myeloma patient samples, CMMC counts correlated with other clinical measures of disease burden, including the percentage of bone marrow plasma cells, serum M protein, and International Staging System stage. CMMC counts decreased significantly from baseline when a remission was achieved due to treatment (P < 0·001). Patients with CMMC counts ≥100 at remission showed reduced survival relative to patients with CMMC counts <100. Patients with undetectable CMMC in remission showed further overall survival benefits. In the SMM cohort, there was a trend toward higher CMMC in patients with higher-risk myeloma precursor states. Significantly higher CMMC counts were observed between intermediate/high risk SMM patients that progressed versus those without progression (P = 0·031). CMMC allow a non-invasive means of monitoring tumour biology and may have use as a prognostic test for patients with plasma cell disorders.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Foulk B, Schaffer M, Gross S, et al. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br J Haematol. 2017. PMID: 29105742. doi:10.1111/bjh.15003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。